{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T04:57:51Z","timestamp":1784869071445,"version":"3.55.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T00:00:00Z","timestamp":1727481600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals Incorporated","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.clinthera.2024.09.023","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T10:06:13Z","timestamp":1730973973000},"page":"29-36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Clinical Burden and Health Care Resource Utilization Associated With Managing Sickle Cell Disease With Recurrent Vaso-occlusive Crises in England"],"prefix":"10.1016","volume":"47","author":[{"given":"Chuka","family":"Udeze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelly F.","family":"Ly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona C.","family":"Ingleby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia D.","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah C.","family":"Conner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farrukh","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clinthera.2024.09.023_bib0001","doi-asserted-by":"crossref","first-page":"e291","DOI":"10.1093\/pubmed\/fdx172","article-title":"How many people have sickle cell disease in the UK?","volume":"40","author":"Dormandy","year":"2018","journal-title":"J Public Health (Oxf)"},{"key":"10.1016\/j.clinthera.2024.09.023_tboref0001","unstructured":"Scottish Paediatric and Adult Haemoglobinopathies Network Annual Report 2021\/22. Accessed October 2023; 2023."},{"key":"10.1016\/j.clinthera.2024.09.023_bib0003","unstructured":"National Haemoglobinopathy Registry. Annual Data Report 2020\/21. Accessed 30 August, 2023. Available from: https:\/\/nhr.mdsas.com\/wp-content\/uploads\/2022\/03\/NHR_DataReport2021.pdf."},{"key":"10.1016\/j.clinthera.2024.09.023_bib0004","doi-asserted-by":"crossref","first-page":"727905","DOI":"10.1155\/2013\/727905","article-title":"The impact of migrations on the health services for rare diseases in Europe: the example of haemoglobin disorders","volume":"2013","author":"Angastiniotis","year":"2013","journal-title":"Sci World J"},{"key":"10.1016\/j.clinthera.2024.09.023_bib0005","doi-asserted-by":"crossref","first-page":"18010","DOI":"10.1038\/nrdp.2018.10","article-title":"Sickle cell disease","volume":"4","author":"Kato","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"16","key":"10.1016\/j.clinthera.2024.09.023_bib0006","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1056\/NEJMra1510865","article-title":"Sickle cell disease","volume":"376","author":"Piel","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2024.09.023_bib0007","doi-asserted-by":"crossref","unstructured":"Rai, P. and K.I. Ataga, Drug therapies for the management of sickle cell disease. F1000Res, 2020. 9.","DOI":"10.12688\/f1000research.22433.1"},{"issue":"10091","key":"10.1016\/j.clinthera.2024.09.023_bib0008","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0140-6736(17)30193-9","article-title":"Sickle cell disease","volume":"390","author":"Ware","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.clinthera.2024.09.023_bib0009","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/ejh.13430","article-title":"The vaso-occlusive pain crisis in sickle cell disease: Definition, pathophysiology, and management","volume":"105","author":"Darbari","year":"2020","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.clinthera.2024.09.023_bib0010","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/ajh.20336","article-title":"Hospital readmission for adult acute sickle cell painful episodes: frequency, etiology, and prognostic significance","volume":"79","author":"Ballas","year":"2005","journal-title":"Am J Hematol"},{"issue":"4 Suppl","key":"10.1016\/j.clinthera.2024.09.023_bib0011","doi-asserted-by":"crossref","first-page":"S536","DOI":"10.1016\/j.amepre.2010.01.001","article-title":"Emergency department visits made by patients with sickle cell disease: a descriptive study, 1999-2007","volume":"38","author":"Yusuf","year":"2010","journal-title":"Am J Prev Med"},{"issue":"35","key":"10.1016\/j.clinthera.2024.09.023_bib0012","doi-asserted-by":"crossref","first-page":"e4528","DOI":"10.1097\/MD.0000000000004528","article-title":"Quality of care in sickle cell disease: Cross-sectional study and development of a measure for adults reporting on ambulatory and emergency department care","volume":"95","author":"Evensen","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"8","key":"10.1016\/j.clinthera.2024.09.023_bib0013","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1007\/s12325-023-02545-7","article-title":"Economic and clinical burden of managing sickle cell disease with recurrent vaso-occlusive crises in the United States","volume":"40","author":"Udeze","year":"2023","journal-title":"Adv Ther"},{"key":"10.1016\/j.clinthera.2024.09.023_bib0014","doi-asserted-by":"crossref","first-page":"102567","DOI":"10.1016\/j.bcmd.2021.102567","article-title":"Co-morbidities and mortality in patients with sickle cell disease in England: a 10-year cohort analysis using hospital episodes statistics (HES) data","volume":"89","author":"Piel","year":"2021","journal-title":"Blood Cells Mol Dis"},{"issue":"6","key":"10.1016\/j.clinthera.2024.09.023_bib0015","doi-asserted-by":"crossref","DOI":"10.1093\/ije\/dyz034","article-title":"Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum","volume":"48","author":"Wolf","year":"2019","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.clinthera.2024.09.023_bib0016","unstructured":"Medicine and Healthcare Products Regulatory Agency. Release Notes: CPRD Aurum March 2022. Accessed October 2023. Available from: https:\/\/cprd.com\/sites\/default\/files\/2022-03\/2022-03%20CPRD%20Aurum%20Release%20Notes.pdf."},{"key":"10.1016\/j.clinthera.2024.09.023_bib0017","unstructured":"National Health Service. Hospital admitted patient care activity 2020-21. Accessed October 2023. Available from: https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/hospital-admitted-patient-care-activity\/2020-21."},{"issue":"3","key":"10.1016\/j.clinthera.2024.09.023_bib0018","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-thalassemia","volume":"384","author":"Frangoul","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2024.09.023_bib0019","unstructured":"Office for National Statistics. Average age at death, by sex, UK. The Health Foundation. Accessed August 18, 2023. Available from: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/healthandsocialcare\/healthandlifeexpectancies\/datasets\/averageageatdeathbysexuk."},{"key":"10.1016\/j.clinthera.2024.09.023_bib0020","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/978-1-4939-7299-9_2","article-title":"Genetic basis and genetic modifiers of beta-thalassemia and sickle cell disease","volume":"1013","author":"Thein","year":"2017","journal-title":"Adv Exp Med Biol"},{"issue":"2","key":"10.1016\/j.clinthera.2024.09.023_bib0021","doi-asserted-by":"crossref","first-page":"E38","DOI":"10.1002\/ajh.24961","article-title":"A descriptive study of the characteristics of older adults with sickle cell disease","volume":"93","author":"Khan","year":"2018","journal-title":"Am J Hematol"},{"issue":"17","key":"10.1016\/j.clinthera.2024.09.023_bib0022","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1182\/blood-2018-03-818161","article-title":"How I treat the older adult with sickle cell disease","volume":"132","author":"Thein","year":"2018","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clinthera.2024.09.023_bib0023","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/01.md.0000189089.45003.52","article-title":"Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients","volume":"84","author":"Powars","year":"2005","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.clinthera.2024.09.023_bib0024","doi-asserted-by":"crossref","first-page":"52","DOI":"10.36469\/jheor.2020.12852","article-title":"Medical resource use and costs of treating sickle cell-related vaso-occlusive crisis episodes: a retrospective claims study","volume":"7","author":"Shah","year":"2020","journal-title":"J Health Econ Outcomes Res"},{"issue":"11","key":"10.1016\/j.clinthera.2024.09.023_bib0025","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1080\/13696998.2020.1813144","article-title":"Vaso-occlusive crises and costs of sickle cell disease in patients with commercial, Medicaid, and Medicare insurance - the perspective of private and public payers","volume":"23","author":"Shah","year":"2020","journal-title":"J Med Econ"},{"issue":"Supplement 1","key":"10.1016\/j.clinthera.2024.09.023_bib0026","doi-asserted-by":"crossref","first-page":"13070","DOI":"10.1182\/blood-2022-170161","article-title":"Clinical impact and outcomes of socioeconomic status on patients with sickle cell disease: a pilot study and literature review","volume":"140","author":"Ozdemir","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2024.09.023_bib0027","unstructured":"Institute of Health Equity. Health Equity in England: The Marmot Review 10 Years On. Accessed August 15, 2023. Available from: https:\/\/www.health.org.uk\/sites\/default\/files\/2020-03\/Health%20Equity%20in%20England_The%20Marmot%20Review%2010%20Years%20On_executive%20summary_web.pdf."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824002868?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824002868?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T19:57:06Z","timestamp":1736366226000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291824002868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0149291824002868"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.09.023","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Burden and Health Care Resource Utilization Associated With Managing Sickle Cell Disease With Recurrent Vaso-occlusive Crises in England","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.09.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Vertex Pharmaceuticals Funded the Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}